Detalhe da pesquisa
1.
Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective.
J Med Econ
; 23(11): 1321-1329, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32780608